NASDAQ: BFRI
Biofrontera Inc Stock

$0.71+0.11 (+18.33%)
Updated Jun 30, 2025
BFRI Price
$0.71
Fair Value Price
N/A
Market Cap
$6.73M
52 Week Low
$0.54
52 Week High
$2.22
P/E
-0.54x
P/B
14.34x
P/S
0.19x
PEG
N/A
Dividend Yield
N/A
Revenue
$38.00M
Earnings
-$11.53M
Gross Margin
53.3%
Operating Margin
-28.35%
Profit Margin
-30.3%
Debt to Equity
34.37
Operating Cash Flow
-$11M
Beta
0.92
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

BFRI Overview

Biofrontera Inc. is a biopharmaceutical company focused on the treatment of dermatological conditions. The company offers Ameluz, a prescription drug approved for use in combination with the company's licensor's medical device. Its RhodoLED lamp series is used to provide photodynamic treatment of mild-to-moderate actinic keratosis of the face and scalp. Biofrontera also provides Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 1997 and is headquartered in Woburn, MA.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine BFRI's potential to beat the market

Zen Rating Component Grades

N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Pharmaceutical

Industry Rating
B
BFRI
Ranked
Unranked of 60

Top Ranked Stocks in Industry

View Top Pharmaceutical Stocks

Be the first to know about important BFRI news, forecast changes, insider trades & much more!

BFRI News

Overview

Due Diligence Score

Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BFRI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

BFRI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BFRI is poor value based on its book value relative to its share price (14.34x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.23x)
P/B vs Industry Valuation
BFRI is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more BFRI due diligence checks available for Premium users.

Valuation

BFRI fair value

Fair Value of BFRI stock based on Discounted Cash Flow (DCF)

Price
$0.71
Fair Value
-$0.27
Undervalued by
365.75%
BFRI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

BFRI price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-0.54x
Industry
-31.27x
Market
32.47x

BFRI price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
14.34x
Industry
2.23x
BFRI is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

BFRI's financial health

Profit margin

Revenue
$8.6M
Net Income
-$4.2M
Profit Margin
-48.9%
BFRI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BFRI's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$16.6M
Liabilities
$16.1M
Debt to equity
34.37
BFRI's short-term assets ($15.33M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BFRI's short-term assets ($15.33M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BFRI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$4.1M
Investing
-$3.0k
Financing
$0.0
BFRI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

BFRI vs Pharmaceutical Stocks

TickerZen RatingMarket Cap1d %P/EP/B
BFRI$6.73M+18.27%-0.54x14.34x
SXTCD$6.76M+0.58%0.01x0.45x
SBFMD$6.56M-1.37%-0.29x0.29x
IXHL$6.36M+6.40%-0.18x0.86x
CPHI$5.84M-2.19%-0.84x0.84x

Biofrontera Stock FAQ

What is Biofrontera's quote symbol?

(NASDAQ: BFRI) Biofrontera trades on the NASDAQ under the ticker symbol BFRI. Biofrontera stock quotes can also be displayed as NASDAQ: BFRI.

If you're new to stock investing, here's how to buy Biofrontera stock.

What is the 52 week high and low for Biofrontera (NASDAQ: BFRI)?

(NASDAQ: BFRI) Biofrontera's 52-week high was $2.22, and its 52-week low was $0.54. It is currently -67.93% from its 52-week high and 32.84% from its 52-week low.

How much is Biofrontera stock worth today?

(NASDAQ: BFRI) Biofrontera currently has 9,446,197 outstanding shares. With Biofrontera stock trading at $0.71 per share, the total value of Biofrontera stock (market capitalization) is $6.73M.

Biofrontera stock was originally listed at a price of $88.20 in Oct 29, 2021. If you had invested in Biofrontera stock at $88.20, your return over the last 3 years would have been -99.19%, for an annualized return of -79.94% (not including any dividends or dividend reinvestments).

How much is Biofrontera's stock price per share?

(NASDAQ: BFRI) Biofrontera stock price per share is $0.71 today (as of Jun 30, 2025).

What is Biofrontera's Market Cap?

(NASDAQ: BFRI) Biofrontera's market cap is $6.73M, as of Jul 2, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Biofrontera's market cap is calculated by multiplying BFRI's current stock price of $0.71 by BFRI's total outstanding shares of 9,446,197.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.